Close-Out Visit

1. lut 28, 2025

What Does 'Close-Out Visit’ Mean?

A close-out visit is the final on-site monitoring visit conducted at a clinical trial site after the last participant has completed the study. During this visit, the clinical research associate (CRA) ensures that all study-related activities are properly concluded and that the site is prepared for potential audits or inspections.

The close-out visit involves verifying the completion of all required documentation, resolving any outstanding queries, and confirming the appropriate storage of study materials. It also includes discussions about post-study responsibilities, such as maintaining records and reporting any late-occurring adverse events.

Why Is the 'Close-Out Visit’ Important in Clinical Research?

The close-out visit is crucial in clinical research as it ensures the integrity and completeness of study data. It serves as a final quality control checkpoint, allowing researchers to verify that all protocol requirements have been met and that the data collected is accurate and reliable for analysis.

Furthermore, the close-out visit is essential for regulatory compliance and preparation for potential audits. It helps to maintain the credibility of the study results and protects the rights and safety of study participants by ensuring all ethical and procedural guidelines have been followed throughout the trial.

Good Practices and Procedures

1. Conduct a comprehensive inventory of investigational product, ensuring all unused supplies are accounted for and properly disposed of or returned according to sponsor instructions.
2. Verify that all essential documents, including signed informed consent forms and case report forms, are present and properly archived in the Trial Master File.
3. Ensure that arrangements are in place for long-term storage of study records, typically for a minimum of 25 years, in compliance with regulatory requirements.
4. Confirm that the site has a process in place for reporting any post-study safety information or late-breaking adverse events to the sponsor and ethics committee.
5. Review and document the site’s plan for notifying study participants of the overall trial results, when applicable, as part of good clinical practice.

Related Terms

• Training Compliance
• Primary Endpoint
• Clinical Database